随着时间调整的疾病进展建模:一种新兴的方法来加深对慢性疾病的知识
Hideki Yoshioka1, Ryota Jin2, Akihiro Hisaka2
1Office of Regulatory Science Research, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan; Laboratory of Clinical Pharmacology and Pharmacometrics, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan.
Pharmacology & therapeutics
|May 6, 2024
概括
随着时间调整的疾病进展建模 (DPM-TR) 增强了慢性疾病的理解和预测. 这种计算方法使用生物标记数据来跟踪长期变化,帮助药物开发和临床实践.
科学领域:
- 计算生物学和生物信息学
- 生物标志物研究和疾病建模.
- 神经退行性疾病研究
背景情况:
- 对阿尔茨海默病的第一个疾病修饰药物标志着治疗的重大进步.
- 了解疾病进展需要分析多个生物标志物的长期连续变化,而不仅仅是当前的症状.
- 这种基于生物标志物的概念支着新兴的计算方法.
研究的目的:
- 审查疾病进展模拟与时间调整 (DPM-TR) 的新兴计算方法.
- 探索DPM-TR在临床实践和药物开发中的机会.
- 讨论DPM-TR.目前的状况和挑战.
主要方法:
- DPM-TR集成了对多种疾病生物标志物的短期临床观察.
- 它采用数据驱动的方法来模拟几十年来疾病的进展.
- 该方法已应用于神经退行性和非神经退行性疾病.
主要成果:
- DPM-TR能够更准确地了解慢性疾病的进展.
- 它提高了预测个体疾病的阶段.
- 这种方法已经显示出超出神经退行性疾病的适用性.
结论:
- DPM-TR为分析复杂的长期疾病轨迹提供了一个强大的工具.
- 它的应用对推进临床实践和加速各种慢性疾病的药物开发具有重大前景.
- 为了应对当前的挑战,需要进一步开发和验证.
相关概念视频
Introduction To Survival Analysis
221
Survival analysis is a statistical method used to study time-to-event data, where the "event" might represent outcomes like death, disease relapse, system failure, or recovery. A unique feature of survival data is censoring, which occurs when the event of interest has not been observed for some individuals during the study period. This requires specialized techniques to handle incomplete data effectively.
The primary goal of survival analysis is to estimate survival time—the time...
The primary goal of survival analysis is to estimate survival time—the time...
221
Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
Actuarial Approach
76
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
76
Assumptions of Survival Analysis
124
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
124
Comparing the Survival Analysis of Two or More Groups
177
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
177
Kaplan-Meier Approach
133
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
133


